Build my stack
Home · Guides · List of Peptides

List of Peptides and What They Do

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.

Peptides are short chains of amino acids, and the ones people search for fall into six groups: weight-loss (GLP-1) drugs, repair and recovery, skin and hair, growth hormone, brain and mood, and a mixed group of everything else. Only a few are FDA-approved drugs, each for a named use: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), tesamorelin (Egrifta), bremelanotide (Vyleesi), oxytocin (Pitocin) and elamipretide (Forzinity). The others, including retatrutide, BPC-157, TB-500, ipamorelin and CJC-1295, had no FDA-approved product in Drugs@FDA when we searched on 31 October 2026.

Updated 31 October 2026. FDA labels, Drugs@FDA records and papers were checked on 31 October 2026, and the sources are listed at the end.

The legal picture moved this week. On 30 October 2026 HHS published a Federal Register notice (2026-22192, 91 FR 68526) with an interim enforcement discretion policy for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It says HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with those substances under the policy, and that the policy is not binding on HHS or the public. It is not an FDA approval, and the notice itself says compounded drugs are not FDA-approved. Our plain-English explainer and the legal status guide cover what it does and does not change.

How to Read the Status Column

  • FDA approved means the product has an FDA drug label, and the row names the labelled use. It does not cover every use people try.
  • No FDA-approved product means a Drugs@FDA search by the substance name returned no record on 31 October 2026. It says nothing, good or bad, about whether the compound works.
  • Paper cited means the row names the paper it relies on. A row that cites none is not claiming that human efficacy data exist.

The Full List

Metabolic and weight

PeptideAlso calledTypeFDA status and evidence
SemaglutideOzempic, WegovyGLP-1 receptor agonistFDA approved. Wegovy is labelled to reduce excess body weight and maintain the loss in adults with obesity, or with overweight plus a weight-related condition, among other uses. In the Wegovy label's Study 1, mean weight change was -14.9% versus -2.4% on placebo over 68 weeks.
TirzepatideMounjaro, ZepboundGIP and GLP-1 receptor agonistFDA approved. Zepbound is labelled for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is labelled for type 2 diabetes. In the Zepbound label's Study 1, mean weight change on 15 mg was -20.9% versus -3.1% on placebo, with treatment for up to 72 weeks.
RetatrutideLY3437943GIP, GLP-1 and glucagon receptor agonistNo FDA-approved product found in Drugs@FDA. Phase 2 trial (NEJM, 2023): mean weight change at 48 weeks was -24.2% on 12 mg versus -2.1% on placebo.
MazdutideIBI362GLP-1 and glucagon dual agonistNo FDA-approved product found in Drugs@FDA.
CagrilintideAmylin analogueNo FDA-approved product found in Drugs@FDA.
AOD-9604Growth hormone fragmentNo FDA-approved product found in Drugs@FDA.
HGH Fragment 176-191Growth hormone fragmentNo FDA-approved product found in Drugs@FDA.
5-Amino-1MQNNMT inhibitorNo FDA-approved product found in Drugs@FDA.
MOTS-cMitochondrial-derived peptideNo FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026.

Repair, recovery and immune

PeptideAlso calledTypeFDA status and evidence
BPC-157Body Protection CompoundSynthetic pentadecapeptideNo FDA-approved product found in Drugs@FDA. A systematic review published in October 2026 found three small human studies (30 people in total), rated the certainty of evidence very low, and advised against clinical use outside regulated trials. One of the six peptides named in the HHS notice of 30 October 2026.
TB-500Thymosin beta-4 fragment (LKKTETQ)Seven amino acid fragment of thymosin beta-4No FDA-approved product found in Drugs@FDA. A J Am Acad Orthop Surg review (27 October 2026) says TB-500 is often confused with full-length thymosin beta-4, and that direct musculoskeletal evidence for thymosin beta-4 is limited to in vitro and rodent studies. One of the six peptides named in the HHS notice of 30 October 2026.
KPVTripeptideNo FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026.
Thymosin alpha-1ZadaxinThymosin peptideNo FDA-approved product found in Drugs@FDA.
Wolverine stackBPC-157 + TB-500Blend of two peptidesNeither component has an FDA-approved product.

Skin and hair

PeptideAlso calledTypeFDA status and evidence
GHK-CuCopper peptideCopper-binding peptideNo FDA-approved product found in Drugs@FDA.
AHK-CuCopper peptideNo FDA-approved product found in Drugs@FDA.
ArgirelineAcetyl hexapeptide-8Topical peptideNo FDA-approved product found in Drugs@FDA.
Matrixyl 3000Palmitoyl peptidesTopical peptide blendNo FDA-approved product found in Drugs@FDA.
SNAP-8Acetyl octapeptide-3Topical peptideNo FDA-approved product found in Drugs@FDA.
GLOWGHK-Cu + BPC-157 + TB-500Blend of three compoundsNone of the three components has an FDA-approved product.
KLOWGLOW + KPVBlend of four compoundsNone of the four components has an FDA-approved product.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Growth hormone and muscle

PeptideAlso calledTypeFDA status and evidence
SermorelinGHRH 1-29GHRH analogueBrand Geref was FDA approved (two applications from 1990 and 1997). Drugs@FDA lists both as discontinued.
IpamorelinGrowth hormone secretagogueNo FDA-approved product found in Drugs@FDA. FDA lists ipamorelin acetate in Category 2 for 503B outsourcing facilities (page current as of 22 April 2026).
CJC-1295Modified GRF 1-29GHRH analogueNo FDA-approved product found in Drugs@FDA.
TesamorelinEgriftaGrowth hormone-releasing factor analogueFDA approved. Egrifta WR is labelled to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management.
GHRP-2Growth hormone releasing peptideNo FDA-approved product found in Drugs@FDA. FDA lists GHRP-2 in Category 2 for 503B (injectable and nasal routes), page current as of 22 April 2026.
GHRP-6Growth hormone releasing peptideNo FDA-approved product found in Drugs@FDA. FDA lists GHRP-6 in Category 2 for 503B (page current as of 22 April 2026).
HexarelinGrowth hormone secretagogueNo FDA-approved product found in Drugs@FDA.
MK-677IbutamorenGrowth hormone secretagogueNo FDA-approved product found in Drugs@FDA. FDA lists ibutamoren in Category 2 (page current as of 22 April 2026).
IGF-1 LR3Long-acting IGF-1 analogueNo FDA-approved product found in Drugs@FDA.
Follistatin 344Follistatin isoformNo FDA-approved product found in Drugs@FDA.

Brain, mood and sleep

PeptideAlso calledTypeFDA status and evidence
SelankTuftsin analogueNo FDA-approved product found in Drugs@FDA.
SemaxACTH fragment analogueNo FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026.
DihexaResearch compoundNo FDA-approved product found in Drugs@FDA.
DSIPDelta sleep-inducing peptideNeuropeptideNo FDA-approved product found in Drugs@FDA.

Everything else

PeptideAlso calledTypeFDA status and evidence
PT-141Bremelanotide, VyleesiMelanocortin receptor agonistFDA approved. Vyleesi is labelled for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not indicated for postmenopausal women or men.
KisspeptinReproductive hormone peptideNo FDA-approved product found in Drugs@FDA. FDA lists kisspeptin-10 in Category 2 for 503A (page current as of 22 April 2026).
OxytocinHormoneFDA approved. Pitocin is labelled for obstetric use, including induction of labor for a medical indication, and is given intravenously or intramuscularly.
Melanotan IIMT-2Melanocortin agonistNo FDA-approved product found in Drugs@FDA.
EpithalonEpitalonTetrapeptideNo FDA-approved product found in Drugs@FDA. One of the six peptides named in the HHS notice of 30 October 2026.
NAD+Not a peptide. Metabolic cofactorNot a peptide. Included because it is often miscategorised as one.
SS-31ElamipretideMitochondria-targeted peptideFDA approved under accelerated approval as Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. Continued approval may depend on a confirmatory trial.

What Peptides Are

A peptide is a chain of amino acids. The Egrifta WR label, for example, describes tesamorelin as a synthetic analog of growth hormone-releasing factor with a 44 amino acid sequence. The Bureau uses the word the way the market does, so a few non-peptides, NAD+ among them, appear in the tables and are marked as such. See what counts as a peptide and peptide supplements.

The Honest Summary of This List

Counted by FDA status, the list is lopsided. Six compounds on it have an FDA-approved product with a labelled use: semaglutide, tirzepatide, tesamorelin, bremelanotide, oxytocin and elamipretide. Sermorelin had one, now discontinued. Every other compound has no FDA-approved product in Drugs@FDA. Where human data exist for those, the papers we opened are small: the BPC-157 systematic review counted three studies and 30 people. Retatrutide is the clearest exception for trial size, with a 338-person phase 2 trial in the New England Journal of Medicine, but it has no FDA approval.

None of that makes the unapproved compounds uninteresting to research. It makes them a different proposition from an approved drug, and the status column is there so you can see which is which before paying for either.

Where to Go From Here

See also: what a peptide is and where peptides end and proteins begin.

Frequently Asked Questions

What is the list of peptides and what do they do?

The peptides on this list fall into six groups: weight loss, repair and recovery, skin and hair, growth hormone, brain and mood, and everything else. The ones with an FDA-approved use are semaglutide and tirzepatide (weight reduction, and type 2 diabetes for Mounjaro), tesamorelin (excess abdominal fat in HIV-infected adults with lipodystrophy), bremelanotide (hypoactive sexual desire disorder in premenopausal women), oxytocin (obstetric use) and elamipretide (Barth syndrome). For the rest, this page gives what each compound is and its FDA status, and does not claim a benefit.

What do peptides do for the body?

It depends on the peptide. Approved peptide drugs do specific, labelled things: Wegovy and Zepbound are labelled to reduce excess body weight and maintain the loss, Egrifta WR is labelled to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, Vyleesi is labelled for low sexual desire disorder in premenopausal women, and Pitocin is labelled for obstetric use. Compounds with no FDA-approved product have no FDA-reviewed use.

Which peptides are FDA-approved?

Among the compounds on this list: semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), tesamorelin (Egrifta), bremelanotide (Vyleesi), oxytocin (Pitocin and generic products) and elamipretide (Forzinity, under accelerated approval). Sermorelin's brand Geref was approved but is listed as discontinued. We checked current labels on DailyMed and records in Drugs@FDA on 31 October 2026.

Which peptides on the list have no FDA-approved product?

A Drugs@FDA search by name on 31 October 2026 found no record for retatrutide, mazdutide, cagrilintide, BPC-157, TB-500, KPV, thymosin alpha-1, AOD-9604, ipamorelin, CJC-1295, GHK-Cu, semax, selank, melanotan II, epitalon, MOTS-c, dihexa and others on the list. No approval means FDA has not approved the product for any use. It does not say whether the compound works.

Is there human evidence for BPC-157?

Very little. A systematic review published in October 2026 in Acta Orthopaedica Belgica found three human studies with 30 people in total: a retrospective study of knee injections, a retrospective pilot study for interstitial cystitis and a pilot study of intravenous safety. The authors judged the studies to be of poor methodological quality, rated the certainty of the evidence very low, and concluded that BPC-157 should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.

What did HHS say about compounding peptides on 30 October 2026?

HHS published an interim enforcement discretion policy in the Federal Register (notice 2026-22192) for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. It says HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with those substances under the policy, and that the policy is not binding. It is not an FDA approval: the notice itself says compounded drugs are not FDA-approved.

How are peptide drugs taken?

The approved products above are mostly injected. The Zepbound, Mounjaro, Egrifta WR and Vyleesi labels describe subcutaneous injection, and Pitocin is labelled for intravenous and intramuscular use. Semaglutide also comes as a tablet, as Rybelsus and as a Wegovy tablet in the current Wegovy label.

Sources

Every source below was opened on 31 October 2026.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes